Compare MBUU & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBUU | CERS |
|---|---|---|
| Founded | 1982 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | EDP Services |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.4M | 585.1M |
| IPO Year | 2013 | 1996 |
| Metric | MBUU | CERS |
|---|---|---|
| Price | $28.90 | $2.50 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.20 | N/A |
| AVG Volume (30 Days) | 173.5K | ★ 2.8M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.74 | 27.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $807,561,000.00 | $51,326,000.00 |
| Revenue This Year | $2.14 | $19.95 |
| Revenue Next Year | $12.78 | $8.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $23.84 | $1.15 |
| 52 Week High | $39.65 | $3.47 |
| Indicator | MBUU | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 56.15 | 43.26 |
| Support Level | $26.62 | $2.37 |
| Resistance Level | $29.40 | $2.84 |
| Average True Range (ATR) | 0.91 | 0.18 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 64.30 | 41.36 |
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high-end offshore and outboard motorboats, in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Most recently, in 2026, it tied up with Saxdor Yachts, focused on adventure dayboats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.